Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.
What happened
FDA inspected Elemental Herbs Inc. (doing business as ALL good) in Morro Bay, CA, from January 23 to February 3, 2023. FDA found an inadequate quality unit, inadequate oversight of contract manufacturers and out-of-specification results, and an inadequate stability program, including at least seven SPF drug products marketed without adequate data to support their labeled expiration dates. FDA also reviewed labeling and found “ALL good Goop Skin Recovery Balm” promoted for uses that make it an unapproved new drug and misbranded.
What FDA found
The firm did not establish an adequate quality unit with written, followed responsibilities and procedures, including for oversight of contract manufacturers and handling complaints, changes, returns, and specifications.
21 CFR 211.22(a) and 211.22(d)The firm did not adequately investigate out-of-specification contract laboratory results, including Zinc Oxide assay results during stability testing of SPF-20 Coconut lip balm, and did not promptly tell the contract manufacturer.
21 CFR 211.22(a) and 211.22(d)The firm failed to establish an adequate stability program and to support labeled expiration dates for at least seven SPF drug products.
21 CFR 211.166(a)“ALL good Goop Skin Recovery Balm” is an unapproved new drug because its labeled ingredients and intended uses do not conform to the applicable OTC monograph orders and it has no approved application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)“ALL good Goop Skin Recovery Balm” is misbranded because it is a nonprescription drug subject to section 505G but does not comply with that section and is not the subject of an approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Some SPF product labels did not meet Drug Facts labeling requirements, such as missing the title “Drug Facts” and including extraneous verbiage.
21 CFR 201.66(c)(1) and 201.66(d)(7)
What FDA wants
FDA asks the firm to respond in writing within 15 working days, specifying what it has done to address the violations and prevent recurrence. If corrective actions cannot be completed in that time, the firm must state the reasons for delay and its schedule for completion.
Who should pay attention
- companies using contract manufacturers for OTC drug products
- brands selling topical OTC drugs under monograph ingredients
- retailers and distributors that stock ALL good products
This is a summary. Read the original letter on fda.gov.